Arkolith/Insider Trading/CHRS/Form 4

Lanfear Dennis M

President & CEO, DirectorCoherus Oncology, Inc. (CHRS) · full profile →Form 4 · filed Jun 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
18
0 non-derivative · 18 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 29, 2026Disposed to issuer(D)200K——0
May 29, 2026Disposed to issuer(D)400K——0
May 29, 2026Disposed to issuer(D)450K——0
May 29, 2026Disposed to issuer(D)500K——0
May 29, 2026Disposed to issuer(D)500K——0
May 29, 2026Disposed to issuer(D)125K——0
May 29, 2026Disposed to issuer(D)403K——0
May 29, 2026Disposed to issuer(D)403K——0
May 29, 2026Disposed to issuer(D)225K——0
May 29, 2026Grant(A)200K——200K
May 29, 2026Grant(A)400K——400K
May 29, 2026Grant(A)450K——450K
May 29, 2026Grant(A)500K——500K
May 29, 2026Grant(A)500K——500K
May 29, 2026Grant(A)125K——125K
May 29, 2026Grant(A)403K——403K
May 29, 2026Grant(A)403K——403K
May 29, 2026Grant(A)225K——225K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-069621) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Coherus Oncology, Inc.

Build

Ask your agent about CHRS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001104659-26-069621"
Ask your agent
Use Arkolith to summarize insider buying and selling at Coherus Oncology, Inc.
over the last 90 days and cite the filings.